A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets

Eur J Pharmacol. 1992 Dec 15;229(2-3):203-9. doi: 10.1016/0014-2999(92)90556-j.

Abstract

A-77636, ((1R,3S) 3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benz opyran hydrochloride), is a selective dopamine D1 receptor agonist. In a battery of receptor binding assays, A-77636 shows the highest affinity (pKi = 7.40 +/- 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 is an agonist at the dopamine D1 receptors in the fish retina (pEC50 = 8.13; EC50 = 1.1 nM; intrinsic activity = 102% of dopamine) and the rat caudate-putamen (pEC50 = 8.97; intrinsic activity = 134% of dopamine). The compound is functionally inactive at dopamine D2 receptors (EC50 > 10 microM). In rats with unilateral 6-OHDA (6-hydroxydopamine) lesions of the nigro-striatal dopaminergic pathway, A-77636 elicits prolonged (> 20 h) contralateral turning that is blocked by SCH 23390, a D1 receptor antagonist, but not by haloperidol at doses selective for the dopamine D2 receptor. Higher doses of A-77636 produce forelimb clonus in rats and mice. When tested in marmosets treated with MPTP to induce a parkinsonian-like state, A-77636 increases locomotor activity and decreases the severity of the parkinsonian-like symptoms: the compound is active after either subcutaneous or oral administration. A-77641, the optical antipode of A-77636, has a lower affinity towards the dopamine D1 receptor (pKi = 5.14, Ki = 7200 nM), is less potent as a dopamine D1 receptor agonist (pEC50 = 5.65; EC50 = 2200 nM), fails to elicit turning in the 6-OHDA-lesioned rat, and lacks antiparkinsonian efficacy in the MPTP-treated marmoset.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Adamantane / administration & dosage
  • Adamantane / analogs & derivatives*
  • Adamantane / metabolism
  • Adamantane / pharmacology
  • Administration, Oral
  • Animals
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / metabolism
  • Antiparkinson Agents / pharmacology*
  • Benzazepines / pharmacology
  • Benzopyrans / administration & dosage
  • Benzopyrans / metabolism
  • Benzopyrans / pharmacology*
  • Binding Sites
  • Callithrix
  • Cell Line
  • Dopamine Agents / administration & dosage
  • Dopamine Agents / metabolism
  • Dopamine Agents / pharmacology*
  • Fishes
  • Injections, Subcutaneous
  • Mice
  • Motor Activity / drug effects
  • Oxidopamine / pharmacology
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / drug therapy*
  • Rats
  • Receptors, Dopamine D1 / drug effects
  • Receptors, Dopamine D1 / metabolism*

Substances

  • Antiparkinson Agents
  • Benzazepines
  • Benzopyrans
  • Dopamine Agents
  • Receptors, Dopamine D1
  • A 77636
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Oxidopamine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Adamantane